Zevra Therapeutics Past Earnings Performance
Past criteria checks 0/6
Zevra Therapeutics's earnings have been declining at an average annual rate of -18.6%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 6.9% per year.
Key information
-18.6%
Earnings growth rate
53.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 6.9% |
| Return on equity | -128.5% |
| Net Margin | -366.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results
Nov 15
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%
Aug 30Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Jul 12Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically
Apr 07Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
Apr 04Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Apr 02Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
Dec 28Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts
Sep 05This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year
Aug 20Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
Apr 17US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results
Mar 10Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?
Mar 08Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates
Nov 16Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?
Nov 11KemPharm posts Phase 1 data to support further studies for sleep disorder therapy
Sep 28KemPharm wins Buy rating at Canaccord on CNS focus
Sep 15Revenue & Expenses Breakdown
How Zevra Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 24 | -90 | 54 | 44 |
| 30 Jun 24 | 24 | -67 | 44 | 46 |
| 31 Mar 24 | 28 | -49 | 38 | 43 |
| 31 Dec 23 | 27 | -46 | 35 | 39 |
| 30 Sep 23 | 17 | -20 | 25 | 34 |
| 30 Jun 23 | 17 | -17 | 23 | 27 |
| 31 Mar 23 | 9 | -38 | 20 | 25 |
| 31 Dec 22 | 10 | -27 | 16 | 19 |
| 30 Sep 22 | 11 | -35 | 13 | 16 |
| 30 Jun 22 | 10 | -30 | 11 | 12 |
| 31 Mar 22 | 20 | -17 | 10 | 10 |
| 31 Dec 21 | 29 | -63 | 9 | 10 |
| 30 Sep 21 | 28 | -65 | 9 | 10 |
| 30 Jun 21 | 28 | -66 | 9 | 9 |
| 31 Mar 21 | 23 | -55 | 8 | 8 |
| 31 Dec 20 | 13 | -13 | 8 | 8 |
| 30 Sep 20 | 12 | -14 | 7 | 8 |
| 30 Jun 20 | 22 | -8 | 10 | 10 |
| 31 Mar 20 | 15 | -18 | 11 | 12 |
| 31 Dec 19 | 13 | -25 | 11 | 19 |
| 30 Sep 19 | 11 | -24 | 13 | 23 |
| 30 Jun 19 | 0 | -42 | 12 | 32 |
| 31 Mar 19 | 0 | -43 | 13 | 38 |
| 31 Dec 18 | 0 | -56 | 13 | 41 |
| 30 Sep 18 | 0 | -62 | 13 | 41 |
| 30 Jun 18 | 0 | -57 | 13 | 33 |
| 31 Mar 18 | 0 | -53 | 13 | 28 |
| 31 Dec 17 | 0 | -43 | 13 | 20 |
| 30 Sep 17 | 0 | -43 | 13 | 23 |
| 30 Jun 17 | 0 | -45 | 13 | 21 |
| 31 Mar 17 | 0 | -30 | 14 | 21 |
| 31 Dec 16 | 0 | -17 | 14 | 20 |
| 30 Sep 16 | 0 | -16 | 14 | 17 |
| 30 Jun 16 | 0 | -13 | 13 | 17 |
| 31 Mar 16 | 0 | -52 | 12 | 15 |
| 31 Dec 15 | 0 | -55 | 9 | 14 |
| 30 Sep 15 | 0 | -57 | 8 | 15 |
| 30 Jun 15 | 0 | -55 | 7 | 14 |
| 31 Mar 15 | 0 | -29 | 5 | 13 |
| 31 Dec 14 | 0 | -24 | 5 | 12 |
| 30 Sep 14 | 0 | -14 | 3 | 7 |
Quality Earnings: ZVRA is currently unprofitable.
Growing Profit Margin: ZVRA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ZVRA is unprofitable, and losses have increased over the past 5 years at a rate of 18.6% per year.
Accelerating Growth: Unable to compare ZVRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZVRA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: ZVRA has a negative Return on Equity (-128.51%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:21 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zevra Therapeutics, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dewey Steadman | Canaccord Genuity |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Louise Chen | Cantor Fitzgerald & Co. |